Myasthenia Gravis Complicating the Surgical Management of Achondroplasia: a Case-based Update

Overview

Journal Childs Nerv Syst

Specialty Pediatrics

Date 2022 Jul 30

PMID 35908138

Authors

Fardad T Afshari

Amitav Parida

Phillip Debenham

Guirish A Solanki

Affiliations

Soon will be listed here.

Abstract

Background: Achondroplasia is the commonest skeletal dysplasia of autosomal dominant inheritance caused by "gain of function" mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Foramen magnum compression due to accelerated ossification and spinal canal stenosis secondary to reduced interpedicular distance is a hallmark of achondroplasia, driven by G380R nucleotide pair substitution. In severe cases, limb weakness and neurogenic claudication will require surgical decompression. Rarely, a neurological condition may mimic the compressive spinal dysfunction and therefore, non-surgical causes must also be considered in cases of acute neurological deterioration in children with achondroplasia. Myasthenia gravis (MG) is an autoimmune condition resulting in fatigable muscle weakness. There are no reported cases of myasthenia gravis in achondroplasia in the literature.

Results: We report a child with achondroplasia scheduled for decompressive surgery for severe lumbar canal stenosis presenting with neurological claudication and knee weakness. While waiting for surgery during the COVID-19 pandemic, she developed generalized fatigability and severe weakness raising concerns of acute worsening of cord compression. Urgent investigations ruled out spinal cord compression but identified an unexpected concurrent myasthenia gravis with positive antibodies to acetylcholine receptors. The surgical intervention was postponed averting the potential risk of life-threatening anaesthetic complications. She was successfully managed with a combination of pyridostigmine, steroids, azathioprine, and plasma exchange.

Conclusion: We report the first case of myasthenia gravis in achondroplasia and review implications in the management.

References

OConnell K, Ramdas S, Palace J . Management of Juvenile Myasthenia Gravis. Front Neurol. 2020; 11:743. PMC: 7393473. DOI: 10.3389/fneur.2020.00743. View

Lazaridis K, Tzartos S . Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management. Front Neurol. 2020; 11:596981. PMC: 7734299. DOI: 10.3389/fneur.2020.596981. View

Carlisle E, Ting B, Abdullah M, Skolasky R, Schkrohowsky J, Yost M . Laminectomy in patients with achondroplasia: the impact of time to surgery on long-term function. Spine (Phila Pa 1976). 2010; 36(11):886-92. DOI: 10.1097/BRS.0b013e3181e7cb2a. View

Qureshi A, Choundry M, Mohammad Y, Chua H, Yahia A, Ulatowski J . Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monit. 2004; 10(12):CR684-9. View

Afshari F, Slator N, Fayeye O, Ramakrishnan P, Solanki G . Spinal canal stenosis in children with achondroplasia: the role of augmentation laminoplasty-a 15-year single institution experience. Childs Nerv Syst. 2022; 39(1):229-237. DOI: 10.1007/s00381-022-05566-9. View

Shiang R, Thompson L, Zhu Y, Church D, Fielder T, Bocian M . Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994; 78(2):335-42. DOI: 10.1016/0092-8674(94)90302-6. View

King J, Vachhrajani S, Drake J, Rutka J . Neurosurgical implications of achondroplasia. J Neurosurg Pediatr. 2009; 4(4):297-306. DOI: 10.3171/2009.3.PEDS08344. View

Arnheim N, Calabrese P . Germline Stem Cell Competition, Mutation Hot Spots, Genetic Disorders, and Older Fathers. Annu Rev Genomics Hum Genet. 2016; 17:219-43. PMC: 5007215. DOI: 10.1146/annurev-genom-083115-022656. View

Shrager J . Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2017; 375(20):2005-2006. DOI: 10.1056/NEJMc1611704. View

10.

Heliopoulos I, Patlakas G, Vadikolias K, Artemis N, Kleopa K, Maltezos E . Maximal voluntary ventilation in myasthenia gravis. Muscle Nerve. 2003; 27(6):715-9. DOI: 10.1002/mus.10378. View

11.

Vajo Z, Francomano C, Wilkin D . The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev. 2000; 21(1):23-39. DOI: 10.1210/edrv.21.1.0387. View

12.

Finnis M, Jayawant S . Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011; 2011:404101. PMC: 3206364. DOI: 10.4061/2011/404101. View

13.

Haroun-Bizri S, Maalouli J, Deeb P, Baraka A . Anesthetic management for a patient with myasthenia gravis undergoing coronary artery bypass graft. Middle East J Anaesthesiol. 2003; 17(2):299-305. View

14.

Bellus G, Hefferon T, Ortiz de Luna R, Hecht J, Horton W, Machado M . Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet. 1995; 56(2):368-73. PMC: 1801129. View

15.

Barrons R . Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy. 1997; 17(6):1220-32. View

16.

Goriely A, Wilkie A . Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease. Am J Hum Genet. 2012; 90(2):175-200. PMC: 3276674. DOI: 10.1016/j.ajhg.2011.12.017. View

17.

Jones S, Sorbello A, Boucher R . Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011; 34(10):839-47. DOI: 10.2165/11593110-000000000-00000. View

18.

Dillon F . Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol. 2004; 24(1):83-94. DOI: 10.1055/s-2004-829587. View

19.

Sciubba D, Noggle J, Marupudi N, Bagley C, Bookland M, Carson Sr B . Spinal stenosis surgery in pediatric patients with achondroplasia. J Neurosurg. 2007; 106(5 Suppl):372-8. DOI: 10.3171/ped.2007.106.5.372. View